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Introduction
Respiratory syncytial virus (RSV) is an important cause of annual 
epidemics of bronchiolitis and pneumonia in children less than 
five years of age worldwide1–5. The most severe disease occurs 
among infants under 6 months of age6, making this group the 
principal target for RSV disease prevention.
To date there are no licensed vaccines for RSV. However, 
strategies to protect the young infant through immunisation 
are underway. One approach showing particular promise is to 
protect the infant over the first few months of life by maternal 
vaccination. A maternal RSV vaccine which is based on a 
post-fusion F protein nanoparticle design7, is now undergoing 
phase 3 clinical trials (NCT02624947). Standardised serological 
assays are needed if this or other vaccines show good efficacy 
as they go to effectiveness phase 3b/4 clinical trials.
The plaque reduction neutralisation test (PRNT) has been the 
preferred technique by most studies to determine the correlates 
of protective immunity to RSV8–13. This is because the assay 
determines the level of antibodies present that are presumed 
to be functional in vivo14. For instance, a pseudovirion-based 
neutralisation assay was found to detect all neutralizing 
antibodies that directly arrest the virus and thus to provide 
protection against infection with Human papilloma virus15. A 
study by Piedra et al. showed that serum antibody titres correlate 
with protection8; a finding also supported by Stansbelle et al. 
who showed that neutralisation antibody titres were inversely 
associated with RSV hospitalization in infants <6months16. 
Hence PRNT is considered the most appropriate serological 
assay for use in quantifying protective immunity correlates to 
RSV.
Although the PRNT is considered the “Gold standard” method 
for quantifying the level of RSV specific antibodies, it has 
several limitations: (i) PRNT antibody titres are currently not 
internationally standardised and therefore it is difficult to 
compare results across different studies, though work is under way 
to resolve this17; (ii) the assay procedure is cumbersome - taking 
four to six days (according to method) to complete; and, (iii) the 
assay is costly in terms of laboratory technologist time. Hence, 
the PRNT is not ideal for large sero-epidemiological studies or 
large-scale vaccine trials.
Due to these limitations, it would be beneficial to adopt a 
serological assay which is quicker, cheaper and can be easily 
standardized, for use in large vaccine studies. An ELISA method 
is an option. However, the method measures epitopes of the 
target antigen and does not discriminate antibodies specific to 
neutralizing sites. Presently, there are two RSV specific IgG 
ELISA assays in our laboratory: an ELISA which uses crude 
RSV A2 culture lysate as antigen (Crude ELISA), and a 
commercial ELISA (IBL ELISA) which uses 96 well micro titre 
ELISA plates pre-coated with RSV F protein and RSV group A 
cell extract as antigen. We examined the agreement between 
ELISA assays and the PRNT in quantifying RSV specific 
antibodies using serum samples from a birth cohort in Kilifi, a 
coastal part of Kenya.
Methods
Study site and participants
This study was conducted in Kilifi, within the Kilifi Health and 
Demographic Surveillance System (KHDSS) in the coastal 
part of Kenya18–20. Archived serum and plasma samples were 
utilised arising from the Kilifi Birth Cohort (KBC) study con-
ducted between 2002 and 2007, by the Kenya Medical Research 
Institute-Wellcome Trust Research Programme (KEMRI-WTRP). 
The KBC study was an observational study to investigate 
susceptibility to invasive pneumococcal disease among chil-
dren. In this study, newborn participants numbering around 6000, 
recruited at the maternity ward or the child health clinic of 
Kilifi County Hospital (KCH), were followed for a 2-year period 
with blood samples collected at birth and then every 3 months. 
Samples were stored as plasma (for cord bloods) or serum 
(follow-up samples) at -80°C. Details of the birth cohort study are 
described elsewhere10,18,19.
In the present study, a random sample set of 100 individuals 
from the KBC participants recruited from the KCH maternity 
ward, were selected from the study database. Description of the 
levels of maternal RSV specific neutralizing antibodies from 
blood samples of the 100 participants were provided in a previous 
publication10.
Ethical considerations
All parents and guardians gave written consent to have their 
children participate in the KBC study for storage of blood 
samples for use in future research. The use of the archived 
sample set was approved by the KEMRI-Scientific and Ethics 
Review Unit (SERU# 2307).
Laboratory procedures
Archived plasma/serum samples from the KBC study which 
had been stored at -80°C were retrieved and screened using 3 
serological assay techniques: (i) a PRNT (ii) an IgG ELISA 
assay using crude RSV lysate as antigen (crude ELISA) and 
(iii) an RSV IgG ELISA using a commercial ELISA kit (IBL 
ELISA).
Plaque reduction neutralisation test (PRNT). The PRNT pro-
cedure for determining the titre of RSV neutralising antibodies 
has been described previously9. The method incorporated 
a step in which serum samples were incubated at 56°C in a 
water bath for 30 minutes to inactivate complement cascade 
proteins. Each serum sample was repeatedly diluted 2-fold over 
ten consecutive dilutions and mixed with an equal volume of 
50 plaque forming units (pfu) of RSV A2 virus (RSVA2 and 
Hep2 cells were a kind donation from Dr. Patricia Cane 
while she worked at the Health Protection Agency, UK). The 
virus-serum mixture (50µl per well) was dispensed over a conflu-
ent monolayer of Hep2 cells in a 96 well culture plate, incubated 
at 37°C for 1 hour and then underwent 4-hour cycles of rotation 
on an angled (about 30°) rotating platform (about 40 rev/minute) 
for 10 minutes and incubation in a 37°C CO2 incubator for 
30 minutes. The plate was then incubated for 48 hours in a 
37°C CO2 incubator. Fixation of cells was done by the addition of 
100µl of fixation reagent (30% methanol+70% acetone). Plaques 
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were detected by addition of a primary antibody (RSV F protein 
mouse monoclonal-BIO-RAD, Catalogue# MCA490) solution 
diluted 1:500 in PBS with 2 hours incubation at 37°C, followed 
by an addition of a 100µl/well of an anti-mouse HRP-conjugated 
secondary antibody (170-5047 Immun-Star Goat Anti-Mouse 
(GAM)- IgG (H/L) polyclonal antibody HRP–BIORAD) 
solution diluted 1:1000 in Phosphate Buffered Saline (PBS) with 
1 hour incubation at room temperature. After each step, plates 
were washed manually three times using 200µl/well PBS buffer. 
Plaques were visualised by addition of 100µl/well detection 
reagent. This consisted of 16 µl of hydrogen peroxide and 0.6ml 
of 3-amino-9-ethlycarbazole 3.3mg/ml solution (20mg 3-amino-
9-ethlycarbazole tablet were dissolved in 6.06ml of dimethyl 
sulphoxide (DMSO) to give a 3.3mg/ml solution) to 10ml of 
20mM sodium acetate solution (pH 5.0-5.5). Reading and 
counting of the brown-stained RSV micro-plaques was done 
using an ELISpot reader (Autoimmun Diagnostika GmbH, 
Germany).
The dilution of a test serum sample required to induce 50% 
neutralization of a known titration of RSV A2 virus was deter-
mined using the Spearman Karber method9. In addition, a panel 
of control samples from BEI Resources (BEI RSV Reference 
panel catalogue #NR-32832) was included in each batch of 
the PRNT assay to monitor reproducibility of the assay results 
and deterioration of the antibodies used. Results obtained 
from screening of the BEI samples were compared with PRNT 
values of the samples as previously tested in BEI resources 
laboratories.
Crude RSV lysate IgG ELISA (Crude ELISA). Blood samples 
were tested for antibody concentration with an IgG based 
ELISA method using crude virus extract from lab-adapted RSV 
A2 culture following a local standard operating procedure21. The 
crude virus RSV lysate preparation, optimal dilutions for 
RSV-A2 antigen, the serum dilutions and generation of a standard 
curve from a pooled adult serum were determined by a 
checkerboard titration as previously described21,22. In every run, 
one half of the 96 well plate (column 1-6) was coated with 
50µl/well of RSV lysate (antigen), while the other half (column 
7-12) was coated with 50µl/well of mock lysate (mock). The 
mock consisted of Hep2 cells without RSV virus prepared 
using same procedure as that of the RSV lysate. Plates were 
incubated overnight at 37°C, then blocked for 1 hour with 
200µl/well of 5% skimmed milk at 37°C. Blocking buffer was 
flicked off. Diluted serum samples 100µl/well were dispensed 
to both the antigen and mock sides of the plate. The plates were 
washed 4 times with 200µl/well of 0.05% Tween 20 in PBS 
(PBS-T) using an ELISA plate washer. A secondary antibody 
[polyclonal antibody to human IgG heavy chains (Goat anti human 
IgG HRP antibody-KPL, Catalogue# 074-1002) (100µl/well) 
diluted 1:1000 in PBS buffer was added to each well and incu-
bated for 1 hour at room temperature. The reaction was devel-
oped using 50µl/well of Ortho-Phenylenediamine dihydrochloride 
(OPD, Catalogue# P8412-100TAB, Sigma-Aldrich) solution 
as substrate (prepared just before use in the ratio 1mg of OPD 
in 1 ml of PBS and 1ul of hydrogen peroxide). The intensity of 
colour developed was read at 490nm using an ELISA reader 
(SYNERGY 4, BioTeK). All samples were run in duplicate to 
monitor reproducibility of results and variability arising from 
pipetting. Positive and negative controls were run on every 
plate and plotted on a graph over time to check for antigen 
deterioration of the standards or coating antigen. The OD values 
of the mock were subtracted from the OD values of the antigen 
lysate to give the final OD value of the serum sample. OD values 
of the standard serum dilutions were assigned arbitrary unit (AU) 
values. Serum samples were assigned arbitrary units of RSV 
specific IgG by comparison against a standard curve generated 
from the pooled adult serum (serum standard) tested in each 
ELISA plate.
Commercial RSV IgG ELISA (IBL ELISA). Use of the com-
mercial RSV IgG ELISA kit and the procedure followed 
manufacturer’s guidelines as described in the package insert 
(Cat#: RE56881- IBL International GmbH, D-22335 Hamburg, 
Germany). The ELISA procedure was based on a sandwich 
principle. In this assay, the 96 well plates were pre-coated 
with Vero E6 cells; strain long, F-protein; cell extract of RSV 
subgroup A (long strain) containing F-protein as well as 
G-protein as antigen (IBL communication). Specific antibodies 
from the serum samples binding to the pre-coated antigen were 
detected by a secondary antibody, rabbit anti-human conjugated 
to horse radish peroxidase enzyme. The reaction was developed 
using Tetramethylbenzidine(TMB) solution as substrate. The 
intensity of the colour developed, which is proportional to the 
concentration of IgG-specific antibodies detected, was read at 
450nm using an ELISA reader (SYNERGY 4, BioTeK). The 
concentration of RSV IgG antibodies from the samples was 
estimated by comparison with a standard curve fit using a four 
parameter logistic regression model conducted in a GraphPad 
Prism software version 7.03.
Statistical analyses
Data analysis was conducted using STATA version 13.1 (College 
Station, Texas). The laboratory data were merged with archived 
data from the KBC participant’ databases for analysis. Sample 
PRNT titres were logarithmically transformed (base 2) for all 
statistical analyses.
Correlation analyses between PRNT antibodies (log2PRNT) 
and IgG ELISA (log10) antibodies was done using a Pearson 
correlation test. Agreement between PRNT and ELISA was 
done using Bland-Altman plots23. For each serum sample, the 
difference between PRNT and ELISA result was plotted against 
the averages of both assays. During Bland-Altman analysis, 
concentrations for RSV IgG IBL ELISA and crude lysate RSV 
IgG ELISA were log transformed to (base 2) and the data tested 
for normality. Modified Bland-Altman plots were used to test 
the effect of age on agreement between ELISA and PRNT. 
Regression analysis between ELISA and PRNT was used to 
estimate the 95% prediction intervals of PRNT antibodies by 
IgG ELISA method. The standard error (SE) of the predicted 
PRNT titre for an individual was estimated using the 
formula:
1( 1 ) ,SE RMS
n
 
= +  
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Where, RMS is the residual mean squares and n is the number 
of observations. The predicted mean of PRNT titre by an ELISA 
method was calculated using the formula:
,y mx c= +
Where y is the predicted PRNT titre, m is the regression coeffi-
cient, x is the RSV antibody concentration by ELISA measure-
ment and c is the y intercept where x=0. The upper and lower 
95% prediction intervals were calculated using the formula: 
Upper/Lower 95% prediction limit = (mx+c) +/- 1.96SE, where 
SE is the standard error (see full methods here).
Results
Baseline characteristics
Archived sera from 100 cohort participants were selected. 
However, for 1 participant, the samples were not sufficient to 
screen for ELISA IgG antibodies after screening for PRNT 
titres. A total of 229 samples (99 cord samples, 87 three-month 
samples and 43 six-month samples) from the 99 participants 
were therefore available with data for the 3 serological assays. 
The mean gestational age at birth was 38.5 weeks (95% 
CI 37.6 – 39.3), while the mean birth weight was 2.9 kilograms 
(95% CI 2.7 – 3.0). The mean concentration of log2PRNT 
titres were: cord blood samples, 10.6 log2PRNT (95% 
Confidence interval, CI; 10.3– 10.8); 3 months of age samples; 
8.3 log2PRNT (95% CI 8.1 – 8.6); and 6 months and over 
7.6 log2PRNT (95% CI 7.1 – 8.1). The highest PRNT titre 
observed among these participants was 12.9 log2PRNT while the 
lowest was 5.1 log2PRNT.
QA results
The mean PRNT titre results of a panel of 5 reference samples 
from BEI Resources tested in our laboratory were within range 
of the PRNT titre results as tested in BEI in 2011. These results 
are shown in Table 1.
Comparison of ELISA with PRNT
A Pearson correlation test to determine the strength of asso-
ciation between ELISA antibodies and neutralizing antibody 
(Figure 1), showed a strong positive correlation between PRNT 
titres and IBL ELISA antibody (r=0.75), and moderate posi-
tive correlation between PRNT titres and crude ELISA antibody 
(r=0.61). The two correlations were each statistically significant 
(P=0.0001).
The distribution of log transformed RSV antibody concentrations 
were approximately log- normal for each ELISA dataset and for 
the PRNT data. Bland-Altman plots were drawn to assess the 
agreement between PRNT and ELISA in quantifying a high or 
low RSV specific antibody level from a sample (Figure 2). In this 
analysis, 95% of samples were observed to fall within the 95% 
level of agreement between PRNT and IBL ELISA and 96% of 
samples between PRNT and crude ELISA, respectively. The 
Bland-Altman plots showed a mean difference of 4.5 log2 
PRNT (95% limits 1.3-7.6) between PRNT and IBL ELISA and 
2.1 log2 PRNT (95% limits -1.9-6.2) between PRNT and crude 
ELISA. Crude RSV lysate IgG ELISA showed a slightly wider 
95% limit of agreement (-1.866, 6.157) compared to IBL RSV 
IgG ELISA (1.392, 7.595).
Modified Bland-Altman plots (Figure 3) show the difference 
in value of the ELISA and PRNT results plotted against age in 
months (i.e. time since birth of collection of the samples). Age 
did not have any appreciable effect on the agreement between 
PRNT and either of the ELISA result.
Further assessment using regression analysis (Figure 4), estimated 
the standard error for predicting the mean PRNT titres by ELISA 
Table 1. Neutralisation test results by Kenya Medical Research Institute 
KEMRI-Wellcome Trust Research Programme (KEMRI-WTRP) and BEI 
laboratories of samples from BEI Resources respiratory syncytial virus (RSV) 
Reference panel catalogue #NR-32832 which contains 5 different pooled 
human polyclonal antisera to RSV.
Reference sample Expected titer range 
provided by BEI
KEMRI-WTRP  
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Figure 2. Bland Altman plots showing agreement between: (a) Commercial IBL respiratory syncytial virus (RSV) IgG ELISA and plaque 
reduction neutralisation test (PRNT) RSV antibody titres (b) Crude RSV lysate IgG ELISA antibody and PRNT RSV antibody titres. The 95% 
limits of agreement, mean difference and averages are also shown for each graph. PRNT and ELISA IgG antibodies are presented using 
base2 log scale.
Figure 1. Scatter plots showing correlation between: (a) Commercial IBL respiratory syncytial virus (RSV) IgG ELISA and plaque reduction 
neutralisation test (PRNT) RSV antibody titres (b) Crude RSV lysate IgG ELISA antibody and PRNT RSV antibody titres. The spearman 
correlation coefficient (r) is shown. ELISA IgG antibodies are presented using base10 log scale, while PRNT RSV antibodies are presented 
using base 2 log scale.
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Figure 3. Modified Bland Altman scatter plot showing the effect of age on agreement between plaque reduction neutralisation test 
(PRNT) and ELISA assays. Panel A is a graph for difference between PRNT and Commercial IBL respiratory syncytial virus (RSV) IgG ELISA 
against age and panel B is a graph for difference between PRNT and Crude RSV lysate IgG ELISA against age. The short dashed gray lines 
represent the 95% limits of agreement, solid gray line represent the mean difference of agreement for each graph. PRNT and ELISA IgG 
antibodies are presented using base2 log scale.
Figure 4. Scatter plots and regression analysis showing respiratory syncytial virus (RSV) specific antibody predictions between: (a) IBL 
RSV IgG ELISA and plaque reduction neutralisation test (PRNT) RSV antibody titres (b) Crude RSV lysate IgG ELISA antibody and PRNT 
RSV antibody titres. The 95% prediction intervals are shown for each graph by blue dashed lines, while the predicted mean for PRNT 
measurements by ELISA are shown using continuous black line. Black hollow circles represent individual antibody levels. ELISA IgG 
antibodies are presented using base10 log scale, while PRNT RSV antibodies are presented using base 2 log scale.
Page 7 of 17
Wellcome Open Research 2019, 4:33 Last updated: 04 APR 2019
method to be 1.204 and 1.424 for IBL ELISA and crude ELISA, 
respectively. All samples with low concentrations of RSV spe-
cific antibody were within the 95% prediction limit for crude RSV 
lysate IgG ELISA (Figure 4b). The predicted PRNT values by 
IBL ELISA were given as (1.880x + 6.517), while the predicted 
PRNT values by crude ELISA were given as (1.419x +6.164). 
The 95% prediction limits for PRNT antibodies were slightly 
higher for crude ELISA +/- 2.79 log2PRNT compared to IBL 
ELISA +/-2.36 log2PRNT.
Discussion
To overcome the challenges experienced with PRNT as a tech-
nique for quantifying protective immunity correlates to RSV in 
large vaccine studies, we explored how well ELISA and PRNT 
methods agree in detecting levels of RSV specific antibodies, 
and in addition, investigated how accurate an ELISA method can 
predict the PRNT measurements and if it could be considered 
a suitable replacement for PRNT.
We found moderate to good correlations between each ELISA 
(IBL (r =0.75) and crude (r=0.61)) and the reference method for 
neutralizing antibodies, PRNT. The stronger correlation in IBL 
ELISA could be explained by the fact that, both PRNT and IBL 
ELISA methods were designed to target specific antibodies 
against the RSV F and G protein. This is because, neutralising 
antibodies are presumed to dominate within the RSV F pro-
tein also commonly known as the key target for neutralizing 
antibodies24,25. Consequently, there is increasing interest to use the 
RSV F protein as the maternal RSV vaccine candidate antigen7. 
The moderate correlation with crude ELISA is likely caused by the 
wide range of antibodies against multiple RSV antigens the assay 
targets. This might have possibly led to detection of additional 
antibodies specific to other RSV proteins that are missed by 
both IBL ELISA and PRNT assay.
We identified few studies that show correlation between 
ELISA and neutralization assay26–29. Similar findings to our study 
were previously reported by Welch et al, who suggested that 
ELISA measure all antibody types and do not discriminate the 
neutralizing antibodies as measured by functional assays, thus 
cannot be relied upon to predict the neutralizing activity of the 
sera29. Due to the moderate correlation observed in our study 
between PRNT and crude RSV lysate IgG ELISA, we suggest 
that, careful consideration should be made on the choice of 
ELISA based assays as a surrogate for a neutralization assay in 
epidemiological studies.
The Bland-Altman plots demonstrated that 96% of all samples 
fell into the 95% limits of agreement between PRNT and crude 
ELISA. However, the crude ELISA had a slightly wider limit 
of agreement with PRNT compared to IBL ELISA. The PRNT 
values were also consistently higher than for ELISA. The 
wider limit of agreement indicates that the crude RSV lysate 
IgG ELISA has a higher variability with PRNT compared to 
IBL ELISA. This again, raises the issue of specificity and affin-
ity of binding for RSV specific IgG antibodies measured using the 
crude ELISA method. Very few studies have used Bland-Altman 
plots to assess agreement between two serological methods29–32. 
One study which evaluated two commercially available ELI-
SAs and one in-house reference laboratory ELISA for the 
determination of human anti-rabies virus antibodies29, suggested 
that the results from the Bland-Altman plot analysis can only 
offer an insight into the availability of alternative, less complex 
method to monitor antibody titres during vaccine studies.
We also demonstrated that age did not have an appreciable 
effect on the agreement between PRNT and ELISA methods in 
detection of RSV specific antibodies. We performed this analy-
sis because poor correlation between functional antibody and 
antibody concentration is thought to be influenced by age33. 
For instance, samples from infants and the elderly are likely to 
show a poor correlation between PRNT and ELISA usually because 
their receptors don’t activate appropriate T or B cell responses, 
although the antibodies bind to antigen33. However, in this 
study, both methods showed agreement in the level of detected 
antibody for an individual regardless of age.
In this study, we could predict PRNT titres using ELISA with 
moderate accuracy. Using regression analysis, the IBL ELISA 
method predicted the mean PRNT titre at 95% prediction inter-
val within a width of 4.8log2 PRNT, while, crude RSV lysate 
IgG ELISA predicted the mean PRNT titre within a width 
of 5.6 log2 PRNT units. This implies that, the PRNT titre of any 
given serum sample if estimated using an ELISA IgG antibody 
concentration measured directly by the ELISA method would 
fall within 2.4-2.8 fold higher or lower than the true value. 
In a perfect regression, if RSV antibody concentrations were 
measured by ELISA, the corresponding PRNT values would be 
estimated using (1.880x + 6.517) and (1.419x +6.164) for IBL 
ELISA and crude ELISA respectively. With, x being the 
antibody concentration measured directly by the respective ELISA 
method. However, the high variability makes direct estimation 
of PRNT values by the above formula difficult. For instance, 
the 95% upper limit of detecting mean cord PRNT titre of 
10.6 log2PRNT by crude ELISA would be 13.4log2PRNT, which 
is above the highest value (12.9log2PRNT) the PRNT assay 
detected in this study. The combined analysis approach we have 
applied on the data is unique and we think, this could better 
guide the choice of a suitable serological technique for use in 
place of a PRNT assay for large vaccine studies; and espe-
cially if the units of measurements between the two methods are 
different.
The main limitation we highlight in this study is that the 
PRNT assay we are using is difficult to standardize, which com-
plicates comparison of results between laboratories. However, 
during the time this study was conducted there was no RSV 
standard available. Nevertheless, we tried to mitigate this limi-
tation by using a panel of reference serum samples from BEI 
resources to monitor and minimise assay variability and to make 
sure results of the test samples obtained are acceptable. Another 
limitation is the systematic bias observed with analysis using 
Bland-Altman plots. This was due to the differences in metrics 
used to measure RSV specific antibodies by ELISA and PRNT. 
The RSV specific antibodies in ELISA are measured as a 
concentration (log10) while in PRNT assay are measured as 
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titres (log2). The Bland-Altman plots show a trend if analysis is 
done using the respective metrics of the serological assays, thus 
difficulty in estimating the mean difference. The plots in 
Bland-Altman analysis should demonstrate that the two methods 
are consistent in what they are measuring in the same metrics. 
We tried to minimise this by transforming ELISA values to log 
base 2 during Bland-Altman plot analysis.
Conclusions
Both ELISA methods show a moderate-good correlation with 
PRNT in measuring RSV specific antibodies. However, a com-
mercial anti RSV based ELISA antibody assay which has less 
variability and has a high positive correlation with PRNT assay 
in detecting RSV specific antibody responses, does not provide 
an accurate prediction of PRNT antibody values. The true PRNT 
value would lie 2.4 fold higher or 2.4 fold lower if a commer-
cial RSV IgG IBL ELISA is used in place of a PRNT assay. Our 
results suggest that, should PRNT prove unsuitable as a Gold 
standard for quantifying RSV specific antibodies, the utility 
of an ELISA method in vaccine studies should be assessed 
independent of a PRNT assay.
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